- Previous Close
2.4200 - Open
2.4703 - Bid 2.7200 x 100
- Ask 2.4500 x 100
- Day's Range
2.4000 - 2.4799 - 52 Week Range
1.8110 - 11.2000 - Volume
5,642 - Avg. Volume
11,655 - Market Cap (intraday)
45.794M - Beta (5Y Monthly) 0.70
- PE Ratio (TTM)
-- - EPS (TTM)
-2.8400 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
LakeShore Biopharma Co., Ltd, a biopharmaceutical company, engages in the discovering, developing, manufacturing, commercializing, and sale of vaccines and therapeutic biologics for infectious diseases and cancer. The company's product pipeline includes YSJA, a conventional rabies vaccine which is in marketed stage; PIKA, a rabies vaccine which are in phase I/III and preclinical trials for the treatment of rabies virus; PIKA YS-ON-001, an immuno-oncology therapeutic that is in phase I trials for the treatment of pancreatic and hepatocellular cancer; PIKA YS-HBV-001, a hepatitis B vaccine that is in phase I trials; PIKA YS-HBV-002, an immune-therapy vaccine which is in IND preclinical trials for the treatment of chronic HBV infection; and PIKA YS-ON-001 and PIKA Influenza Vaccine which are in preclinical trials. It operates in China, Singapore, the United States, and the Philippines. The company was formerly known as YS Biopharma Co., Ltd. and changed its name to LakeShore Biopharma Co., Ltd in May 2024. The company was founded in 2002 and is based in Beijing, China.
www.ysbiopharm.comRecent News: LSB
View MorePerformance Overview: LSB
Trailing total returns as of 4/1/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LSB
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LSB
View MoreValuation Measures
Market Cap
45.79M
Enterprise Value
89.76M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.40
Price/Book (mrq)
0.55
Enterprise Value/Revenue
0.97
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-75.59%
Return on Assets (ttm)
-13.85%
Return on Equity (ttm)
-65.99%
Revenue (ttm)
573.42M
Net Income Avi to Common (ttm)
-433.46M
Diluted EPS (ttm)
-2.8400
Balance Sheet and Cash Flow
Total Cash (mrq)
246.35M
Total Debt/Equity (mrq)
72.53%
Levered Free Cash Flow (ttm)
-216.49M